Weekly low-dose decitabine plus venetoclax for MDS or AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests a gentler weekly combination of two medicines—decitabine and venetoclax—for people with MDS, AML, or MDS/MPN. The goal is to improve blood counts and disease control while reducing side effects compared with more harsh treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MDS, AML, or MDS/MPN confirmed by a bone marrow/histology review
- Your past records suggest you may respond to “hypomethylating” medicines like decitabine (HMA)
- You are at least 18 years old and able to sign consent
- Your general health is limited (ECOG performance status 3 or higher)
- Your liver and other organ tests are within study limits (or sometimes kidney limits are acceptable, including dialysis)
- You have no key exclusions like certain AML types, pregnancy, or recent prior use of these same drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (decitabine and venetoclax) at a very low, extended dose for people aged 60 or older who have been newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this gentler approach is effective and well-tolerated.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This study tests a combination of venetoclax (a targeted drug) with a mini stem cell transplant (called a microtransplant) using a partially matched donor. It is for people with higher-risk MDS who cannot have a standard transplant.
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your leukemia or MDS from coming back. It is for people whose disease is at high risk for relapse.
This trial tests a combination of two chemotherapy drugs (idarubicin and cytarabine) at lower doses plus a targeted drug called venetoclax for adults newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this reduced-intensity treatment is effective with fewer side effects.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.